Clinical Trial

Novel Biomarkers Related Xuebijing Injection Improves Sepsis

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.
Trial Details
NCT Number NCT06920420
Lead Sponsor Southeast University, China
Conditions Sepsis
Enrollment 30 participants
Start Date 2025-03-30
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-09